NCT02437253View on ClinicalTrials.gov

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Mucopolysaccharidosis Type IMucopolysaccharidosis Type IIMucopolysaccharidosis Type VI
Interventions
DRUG

Adalimumab

Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.

OTHER

Placebo

Saline placebo

Trial Locations (1)

90502

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

All Listed Sponsors
lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT02437253 - Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI | Biotech Hunter | Biotech Hunter